A diagnostic test for the detection of Streptococcus pneumoniae meningitis was developed using monoclonal antibodies (MAbs) to phosphocholine (PC) and non-PC determinants of pneumococcal teichoic acids. These MAbs do not recognize other bacteria that commonly cause meningitis. By using a dot blot assay, these MAbs were compared with a polyvalent pneumococcal capsular omniserum and an antiserum made to whole cells for their ability to 
The rapid diagnosis of pneumococcal infections, in particular meningitis, is of critical importance. Since the highest incidence of pneumococcal meningitis occurs in children less than 2 years of age and because of the high case fatality rate of this infection (7, 10) , a rapid, reliable diagnostic test would greatly improve the prognosis of patients with this disease. Several assay methods have been studied to determine their effectiveness in diagnosing pneumococcal meningitis, such as counterimmunoelectrophoresis (3, 16, 17) , latex agglutination (16, 17) , and coagglutination (4, 14, 16, 17) . The sensitivities of the methods vary among studies, but in general counterimmunoelectrophoresis is the least sensitive, followed by coagglutination and latex agglutination.
A major difficulty in devising a diagnostic assay for pneumococcal meningitis is the multiplicity of capsular serotypes of Streptococcus pneumoniae. Most of the diagnostic assays developed thus far have used a pooled anticapsular serum, commonly omniserum, for the detecting antibody. This type of pooled antiserum suffers from at least two disadvantages. First, because so many different antibodies are included in the pool, the antibody concentration of any one capsular serotype may not be high enough to detect low concentrations of antigen. Second, cross-reactions, in particular with alpha streptococci, have been found to be associated with this antiserum (9) . An alternative approach to using a pooled antiserum would be the use of a single antibody which would react with an antigenic determinant common to all pneumococci. Antibodies to the phosphocholine (PC) determinant of the pneumococcal cell wall and to a determinant in the pneumococcal teichoic acid recognized by the monoclonal antibody (MAb) D3114 /63 have been shown to react with all pneumococci tested and do not react with the other streptococci tested (13) .
The present study was undertaken in part to determine the Antibodies. The MAbs and antisera used in this study are listed in Table 1 . The production of all of these antibodies has been described in earlier publications (1, 2, 6, 13 ELISA. An enzyme-linked immunosorbent assay (ELISA) was set up to determine the level of antigen detected by each of the antibodies and to determine the feasibility of making a more rapid diagnostic test. This procedure consisted of absorbing either 100 1ul of a solution of 108 heat-killed R36A cells per ml (centrifuged in a microdilution plate for 15 min at 1,500 rpm) or 100 p.l of 10 ,ug of PC-BSA per ml (incubated overnight at 4°C) onto a microdilution plate followed by blocking with 1% BSA for 1 h. The subsequent incubations with the antibody and enzyme-labeled conjugate followed standard methods and were identical with those of the dot blot assay, except that incubation was at 37°C. The substrate, a solution of 1 mg ofp-nitrophenyl phosphate (Sigma) per ml in diethanolamine buffer (pH 9.6) was added after the incubation with the enzyme-labeled second antibody and allowed to react for 30 min at room temperature. The reaction was stopped by adding 50 ,ul of 3 N NaOH, and the plate was read with a Titertek Multiskan (Flow Laboratories, McLean, Va.) microdilution plate reader at 405 nm. Values greater than twice the background level were considered positive.
To determine the feasibility of making a more rapid diagnostic assay, the ELISA parameters outlined above were modified to determine the optimal conditions necessary to run the assay in the shortest possible time. The titers of antigen, antibody, and conjugate were determined, and the incubation times and temperature were altered.
Determination of assay sensitivity. A serotype 14 strain, BG-215, was grown in 150 ml of Todd-Hewitt broth supplemented with 0.5% yeast extract for 12 h at 37°C. The culture was divided into three parts; 50 ml was used as whole live bacteria, 50 ml was heat killed at 60°C for 30 min, and 50 ml was pelleted and lysed with a lysing buffer (0.1% sodium deoxycholate, 0.01% sodium dodecyl sulfate, 0.15 M sodium citrate). The number of bacteria present was determined by standard plate count on blood agar for the live and heatkilled (before heating) samples, and a protein concentration (Bio-Rad Laboratories, Richmond, Calif.) was measured for the lysate. Tenfold serial dilutions of each preparation were made in PBS, and 15 The possibility that an inhibition assay would provide a more rapid test system was evaluated by using heat-killed pneumococci as the solid-phase antigen. Randomly selected positive and negative serially diluted spinal fluids were mixed with the screening antibody in the microtiter wells coated with heat-killed pneumococci. The percent inhibition necessary to separate positive and negative samples was selected to be .20% for all the antibodies except HPCM2, where .40% inhibition was chosen ( Table 6 ). The reason for selecting an inhibition of .40% for HPCM2 is evident from (13) . Although D3114/63 is not superior to the anti-PC antibodies for the detection of pneumococcus-infected spinal fluids, it may be useful along with anti-PC antibodies for the identification of pneumococci isolated from patients. Together the two MAbs detected 82% of the culture-positive spinal fluids. The false-negative spinal fluids in our study may have been taken early in the infection before sufficient antigen concentrations had developed for detection. Our assays to determine the level of antigen detected by the antibodies under the defined conditions of this study indicate that 107 live or heat-killed pneumococci per ml, 4 ,ug of lysate protein per ml, or 2 ,ug of PC-BSA per ml is necessary for positive tests with the different assay procedures using the anti-PC A direct ELISA was used to provide a quantitative assay to determine the conditions that would yield a useful result in the shortest possible time. We found that by adjusting the concentrations of the antibody and conjugate the assay could be completed with 15-min incubations for both antibody and conjugate followed by a 10-min incubation with the substrate. The assay time could probably be shortened further by directly conjugating the anti-PC antibody to alkaline phosphatase, thereby eliminating one of the incubation steps. If a similar protocol could be developed for the dot blot assay, this type of modification would be important for the development of an assay that would be useful in a clinical setting.
The inhibition ELISA was examined as an alternative diagnostic assay, since an inhibition format would circumvent the initial absorption step of binding the spinal fluid to the plate necessary in a conventional direct ELISA. The results indicated the feasibility of this method with the HPCM2 anti-PC antibody.
Sorensen (15) found that anti-PC MAbs would bind to beta-lipoprotein in serum and spinal fluids and concluded that these antibodies could not be used for the detection of PC-containing antigens in these fluids because of nonspecific reactions. Our results do not show any problems with nonspecific reactions among the anti-PC MAbs tested. Possibly the difference in the assay technique employed may explain the nonspecific reactions.
Overall, we feel that our results are quite significant because they indicate that, at least in this assay system, readily available IgM anti-PC MAbs are as useful as a mixture of polyclonal antisera for the detection of pneumococcal antigens in biologic samples. IgM antibodies with essentially identical specificity to the IgM anti-PC antibody that we have used have been frequently produced in several laboratories (1, 6) . With proper care of the cell lines it should be much easier to provide these MAbs than the mixture of immune sera currently in use in most pneumococcal diagnostic assays.
